Belt and Road Summit 2025- Deal-making

10–16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 28 August 2025

Single Cell Drug Screening AI Platform

Marco Suen

Founder & CEO at Provectus Therapeutics Limited

Hong Kong, China (Hong Kong)

About

To investigate tumor heterogeneity, we have developed a single-cell culture device capable of isolating and individually culturing over 1.4 million single cells for high-throughput drug testing. Leveraging our proprietary AI model, we can accurately identify drug-resistant single cells, enabling further investigation and more precise prediction of treatment efficacy.

This platform accelerate cancer reserach, R&D progress for advanced therapeutics and predictive diagnostics for personalised cancer treatment.

Project Location

  • China (Hong Kong)

Project Format

  • Private Project

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Feasibility Study Completed

Main Project Sector

  • Technology

Technology

  • Bio-Tech

Total Project Value

  • 2,500,001 to 5,000,000 USD

Investment Capital Required

  • 1,000,001 to 2,500,000 USD

Interested Format of Cooperation

  • Minority Shareholdings
  • Public–private partnership / Concession
  • R&D Cooperation

Preferred Financing Model

  • Equity
  • Open for negotiation

Previous Funding Stage

  • None

Main Service(s) Required

  • Professional Services

Organisation

Provectus Therapeutics Limited

Hong Kong, China (Hong Kong)

Similar opportunities

  • Project

    Afrivolt

    • Yes
    • Debt
    • None
    • Equity
    • Energy Storage
    • Financial Services
    • 50,000,001 USD or above
    • 50,000,001 USD or above
    • Feasibility Study Completed
    • Energy and Natural Resources
    • Private Equity & Venture Capital
    • Public-Private Partnership Project
    • Public–private partnership / Concession

    recado Andrews

    Director Invest SA at Department of Trade and Industry and Competition South Africa

    Pretoria, South Africa

  • Project

    Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)

    • Yes
    • Equity
    • Bio-Tech
    • Technology
    • Joint Venture
    • Private Project
    • R&D Cooperation
    • Seed & Pre-Series
    • Financial Services
    • Business Valuation
    • Corporate Services
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • Minority Shareholdings
    • Institutional Investment
    • Feasibility Study Completed
    • Market Entry Strategic Analysis
    • Private Equity & Venture Capital

    Haiyang Wang

    CEO at Shanghai Haiju Biotechnology Co., Ltd.

    Shanghai, China

  • Project

    Novel Platinum-Based Drug Targeting Tumor Microenvironment (HJ-550 )

    • Yes
    • Equity
    • Bio-Tech
    • Technology
    • Joint Venture
    • Legal Advisory
    • Private Project
    • R&D Cooperation
    • Seed & Pre-Series
    • Financial Services
    • Investment Banking
    • Business Valuation
    • Corporate Services
    • Open for Negotiation
    • Professional Services
    • Minority Shareholdings
    • Feasibility Study Completed
    • Private Equity & Venture Capital

    Haiyang Wang

    CEO at Shanghai Haiju Biotechnology Co., Ltd.

    Shanghai, China